Analysis of an unselected patient cohort with advanced colorectal carcinoma from a maximum care center

• Verfasst von: Zhang, Xin-Wen [VerfasserIn]
• Verfasst von: Mohr, Jutta [VerfasserIn]
• Verfasst von: Halama, Niels [VerfasserIn]
• Verfasst von: Koschny, Ronald [VerfasserIn]
• Titel: Analysis of an unselected patient cohort with advanced colorectal carcinoma from a maximum care center
• Verf.angabe: Xin-Wen Zhang, Jutta Mohr, Niels Halama and Ronald Koschny
• E-Jahr: 2023
• Jahr: December 2023
• Umfang: 8 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 08.01.2025 ; Online veröffentlicht: 29. November 2023
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2023
• Band/Heft Quelle: 43(2023), 12, Seite 5589-5596
• ISSN Quelle: 1791-7530
• DOI: doi:10.21873/anticanres.16761
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: BEVACIZUMAB
• Sach-SW: CANCER
• Sach-SW: chemotherapy
• Sach-SW: CHEMOTHERAPY
• Sach-SW: Colorectal cancer
• Sach-SW: colorectal liver metastases
• Sach-SW: metastases
• Sach-SW: PLUS CETUXIMAB
• Sach-SW: secondary surgery
• Sach-SW: THERAPY
• Sach-SW: time-to-next-treatment
• Sach-SW: TRIALS
• Sach-SW: tumor sidedness
• K10plus-PPN: 1913793818

Abstract

Background/Aim: Systemic treatment for metastatic colorectal cancer (CRC) includes chemotherapy in combination with a targeted antibody. Novel targeted therapies and immunotherapies are introduced for specific molecular subgroups. Prognostic relevant determinants are still under investigation. Patients and Methods: Systemic therapies of an unselected patient cohort with metastatic CRC were retrospectively analyzed. Treatment outcome was evaluated according to time-to-next-treatment (TTNT) and frequency of conversion surgery and compared between subgroups stratified by primary tumor side, molecular profile, sex and age, and metastases sites. Results: More than 50% of patients with locally advanced or metastatic CRC underwent secondary resection after first-line systemic therapy. Rectum carcinoma had the best prognosis under anti-EGFR-antibody treatment. Female patients had a worse prognosis than male patients in late disease stage. Young patients demonstrated poor response to systemic therapy, but a high rate of conversion surgeries. Conversely, elderly patients benefited from systemic therapy but underwent surgery less frequently. Liver and lung metastases had a worse prognosis than other metastases sites, whereas lung metastases were more likely to be resected than liver metastases in early disease stage. Conclusion: Patient age, sex, primary tumor localization, and metastatic sites are prognostic factors that could guide future treatment decisions for the therapy of metastatic CRC.